Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET
Company Participants
Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations
Robert Blum - President & Chief Executive Officer
Fady Malik - Executive Vice President, Research & Development
Stuart Kupfer - Senior Vice President & Chief Medical Officer
Andrew Callos - Executive Vice President & Chief Commercial Officer
Robert Wong - Vice President & Chief Accounting Officer
Ching Jaw - Senior Vice President & Chief Financial Officer
Conference Call Participants
Srikripa Devarakonda - Truist
Salim Syed - Mizuho
Tessa Romero - JPMorgan
Charles Duncan - Cantor Fitzgerald
Yasmeen Rahimi - Piper Sandler
Akash Tewari - Jefferies
Jeff Hung - Morgan Stanley
Jason Zemansky - Bank of America
Jason Butler - JMP Securities
Rohit Bhasin - Needham & Co.
Omari Baruti - Goldman Sachs
Ash Verma - UBS
Dane Leone - Raymond James
Justin Kim - Oppenheimer
Operator
Good afternoon and welcome ladies and gentlemen to Cytokinetics' First Quarter 2023 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for question-and-answer after the presentation. We will allow for one question per participant.
I will now turn the call over to Diane Weiser, Cytokinetic's Senior Vice President of Corporate Communications and Investor Relations. Please, go ahead.
Diane Weiser
Good afternoon and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D will provide updates related to aficamten and other drug candidates comprising our early-stage pipeline. Stuart Kupfer, SVP and Chief Medical Officer will provide further updates on the development program for aficamten. Andrew Callos, EVP and Chief Commercial Officer will speak further about commercial preparation activities for aficamten and the market opportunity. Robert Wong, VP and Chief Accounting Officer will provide a financial overview of the past quarter. And Ching Jaw, SVP and Chief Financial Officer will discuss our financial outlook and corporate development strategies. Finally Robert Blum will provide closing comments and review expected key milestones for 2023.
Please note that portions of the following discussion including our responses to questions contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements.